A phase 1 trial of NMS-293 with topotecan in BRCA wild type ovarian cancer patients
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs NMS 293 (Primary) ; Topotecan
- Indications Ovarian cancer
- Focus Adverse reactions
- 20 Jan 2025 New trial record
- 13 Jan 2025 According to a Nerviano Medical Sciences media release, company announced U.S. Food and Drug Administration (FDA) has granted IND approval to proceed with two clinical studies in the relapse setting for small cell lung cancer and BRCA wild-type ovarian cancer.